do peptides FAQ

Start with growth hormone-releasing peptides rather than thyroid-targeted compounds. Chronic caloric restriction suppresses both GH pulsatility and thyroid conversion efficiency. GHRP protocols address the GH component first, often producing measurable REE increases within 4–6 weeks as measured by indirect calorimetry. Layer thyroid support (like thymalin) after establishing baseline GH responsiveness. Simultaneously, address the dietary component: reverse dieting at 50–100 calories per week while monitoring body composition prevents rebound fat gain while metabolic signaling normalizes.

Focus on peptides that enhance synaptic plasticity rather than those that prevent acute cell death. Acute neuroprotection (stroke, TBI) requires rapid intervention within the 6–12 hour excitotoxic window. Chronic neurodegeneration (Alzheimer's, Parkinson's) involves progressive synaptic loss, protein aggregation, and mitochondrial dysfunction over years. Dihexa shows efficacy in chronic models because it potentiates BDNF-TrkB signaling that supports ongoing dendritic remodeling. Not just emergency survival signaling. In 12-month-old APP/PS1 mice (late-stage pathology), 30 days of dihexa restored hippocampal synaptophysin expression to 90% of wild-type levels, while P21 showed no structural benefit in the same model (Neurobiol Aging, 2015). Match the peptide mechanism to the disease timeline.

Discard it. Peptides are proteins, and protein denaturation occurs irreversibly above 8°C for most formulations. Reconstituted peptides stored at room temperature for more than 2–4 hours lose structural integrity, meaning the peptide no longer binds to its target receptor even if it looks clear and unchanged. Appearance is not a valid potency indicator. Refrigerate immediately after reconstitution and never attempt to 're-refrigerate' a peptide that's been left warm. The damage is already done.

Consult a physician with peptide prescribing experience before purchasing or using any compound. Cerebrolysin requires intramuscular injection and medical oversight; self-administration without training risks injection site infections or improper dosing. Dihexa and P21 are research-grade compounds not approved for human use outside clinical trials. Purchasing them means you're participating in unregulated self-experimentation. If you're already on stimulant therapy and want to explore adjunctive peptides, frame it as a discussion about neuroplasticity support, not stimulant replacement.

Switch to TB-500 as the primary compound if the injury involves ligaments or tendons (ACL tear, patellar tendinopathy). TB-500 accelerates soft tissue healing by 30–35% in preclinical models through enhanced collagen alignment and reduced scar tissue formation. Dosing for acute injuries: 5mg intramuscular twice weekly for 6–8 weeks, starting within 2 weeks of injury. BPC-157 can be added at 250mcg daily if inflammation is significant, but TB-500 is the lead compound for fresh ligament damage.

This suggests either receptor downregulation (your body adapted to the peptide's signal) or the initial improvement addressed a secondary mechanism while the primary cause remains untreated. Peptides like Dihexa and Cerebrolysin don't typically cause tolerance within two weeks, so returning symptoms more likely indicate that neuroinflammation or mitochondrial dysfunction is still active. Consider rotating peptides or adding a complementary mechanism. For example, pairing Cerebrolysin with Thymalin to address both neuroplasticity and inflammation simultaneously.

Discuss timing with your surgeon. Peptides that promote angiogenesis (BPC-157) may theoretically interfere with controlled healing phases in the first 2–4 weeks post-op. After that window, they may accelerate rehabilitation. TB-500's anti-inflammatory properties could support earlier return to load-bearing activity. No published human trials exist for post-surgical peptide use, so this remains clinical judgment territory.

This is where thymosin peptides show the most intriguing potential. Relapse in IBD often correlates with declining Treg function and loss of microbial tolerance. Thymosin alpha-1's ability to sustain elevated Treg levels suggests maintenance potential, but the longest human trial ran only 12 weeks. Nowhere near the years-long remission maintenance required to declare prevention efficacy. BPC-157 and KPV target active inflammation; their role in asymptomatic periods is unclear. No peptide has demonstrated relapse prevention in controlled trials.

Apply topical GHK-Cu starting 48–72 hours post-surgery once initial hemostasis is complete. Earlier application risks interfering with platelet aggregation. Research shows GHK-Cu reduces scar width by 30–40% when applied during the proliferative phase (days 3–14) rather than the inflammatory phase (days 0–3). Avoid BPC-157 or Tβ4 on fresh incisions unless under medical supervision—excessive angiogenesis during hemostasis can increase hematoma risk.

Most do. Lyophilized (freeze-dried) peptides are the most stable format and tolerate brief periods at room temperature during shipping, but for long-term storage they should be kept at -20°C or colder. Reconstituted peptides and pre-formulated solutions like nasal sprays should always be stored at 2-8°C. Yes. Pre-formulated solutions such as nasal sprays should be stored at 2-8°C (standard refrigerator temperature) and used within the timeframe specified on the product label. Lyophilized peptides can be frozen at -20°C or colder for long-term stability. Avoid repeated freeze-thaw cycles and frost-free freezers (which cycle temperature), as both accelerate degradation. Freeze-dried peptides are the most stable format and can briefly tolerate room temperature, but for long-term storage they should be kept at -20°C or colder. Refrigerate solution and reconstituted forms at 2-8°C (36-46°F); store lyophilized peptides at -20°C or colder for the long term. Heat, direct sunlight, and freeze-thaw cycling all accelerate degradation.

Most reconstituted peptides remain stable for 2-4 weeks when stored at 2-8°C. Aliquoting and freezing at -20°C can extend stability to several months, though repeated freeze-thaw cycles should be avoided. Yes. Aliquoting and freezing at -20°C extends the stability of reconstituted peptides. Avoid repeated freeze-thaw cycles, which significantly accelerate degradation. Temperature, solution pH, preservatives, light exposure, microbial contamination, and the peptide's own chemical stability all play a role. Peptides containing methionine residues are particularly prone to oxidation. Stemcode nasal sprays are formulated with normal saline, a preservative, and lab-grade water for enhanced stability. Stored at 2-8°C, they maintain potency for the duration indicated on the product label.